Atara Biotherapeutics (ATRA) Competitors $9.48 +0.25 (+2.71%) Closing price 04:00 PM EasternExtended Trading$9.46 -0.02 (-0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATRA vs. ORIC, CTMX, DRUG, SOPH, FDMT, YMAB, ENGN, EPRX, GNFT, and OGIShould you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), SOPHiA GENETICS (SOPH), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), enGene (ENGN), Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), and Organigram Global (OGI). These companies are all part of the "pharmaceutical products" industry. Atara Biotherapeutics vs. Its Competitors Oric Pharmaceuticals CytomX Therapeutics Bright Minds Biosciences SOPHiA GENETICS 4D Molecular Therapeutics Y-mAbs Therapeutics enGene Eupraxia Pharmaceuticals GENFIT Organigram Global Atara Biotherapeutics (NASDAQ:ATRA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability. Do insiders and institutionals hold more shares of ATRA or ORIC? 70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 4.0% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 6.8% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, ATRA or ORIC? Atara Biotherapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Oric Pharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Do analysts rate ATRA or ORIC? Atara Biotherapeutics presently has a consensus price target of $17.75, indicating a potential upside of 87.24%. Oric Pharmaceuticals has a consensus price target of $18.57, indicating a potential upside of 62.20%. Given Atara Biotherapeutics' higher probable upside, equities research analysts clearly believe Atara Biotherapeutics is more favorable than Oric Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57Oric Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ATRA or ORIC? In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 1 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.26 beat Atara Biotherapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Atara Biotherapeutics Neutral Oric Pharmaceuticals Neutral Is ATRA or ORIC more profitable? Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -7.83%. Atara Biotherapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atara Biotherapeutics-7.83% N/A -14.51% Oric Pharmaceuticals N/A -51.14%-46.29% Which has higher valuation and earnings, ATRA or ORIC? Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtara Biotherapeutics$128.94M0.44-$85.40M-$3.72-2.55Oric PharmaceuticalsN/AN/A-$127.85M-$1.87-6.12 SummaryOric Pharmaceuticals beats Atara Biotherapeutics on 9 of the 16 factors compared between the two stocks. Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRA vs. The Competition Export to ExcelMetricAtara BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.02M$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E Ratio-2.5521.1127.1820.14Price / Sales0.44292.18440.78137.14Price / CashN/A42.7337.5058.41Price / Book-0.567.748.085.60Net Income-$85.40M-$54.96M$3.16B$248.43M7 Day Performance18.35%6.04%3.77%5.15%1 Month Performance3.95%4.47%3.90%7.62%1 Year Performance5.10%6.12%34.22%21.56% Atara Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRAAtara Biotherapeutics4.1164 of 5 stars$9.48+2.7%$17.75+87.2%+14.0%$55.02M$128.94M-2.55330ORICOric Pharmaceuticals4.642 of 5 stars$10.65-1.4%$19.17+80.0%+16.7%$920.42MN/A0.0080Analyst ForecastCTMXCytomX Therapeutics4.2022 of 5 stars$2.37-5.2%$5.33+125.0%+84.4%$201.55M$138.10M5.21170News CoverageDRUGBright Minds Biosciences2.4871 of 5 stars$27.33-3.7%$83.25+204.6%+2,493.2%$199.84MN/A-75.91N/ASOPHSOPHiA GENETICS2.3903 of 5 stars$3.25+8.7%$7.00+115.4%-18.9%$199.39M$65.17M0.00520Positive NewsHigh Trading VolumeFDMT4D Molecular Therapeutics2.1296 of 5 stars$3.95-6.8%$29.56+648.2%-80.5%$196.42M$40K0.00120YMABY-mAbs Therapeutics3.2974 of 5 stars$4.22-1.9%$15.60+269.7%-60.6%$194.72M$87.68M-6.59150ENGNenGene2.8149 of 5 stars$3.81+0.3%$23.29+511.2%-57.5%$194.20MN/A0.0031Trending NewsEPRXEupraxia Pharmaceuticals2.1324 of 5 stars$5.54+2.8%$11.00+98.6%+106.0%$193.81MN/A0.0029Gap UpGNFTGENFIT2.0798 of 5 stars$3.69-4.8%$13.00+252.7%-12.2%$193.49M$76.77M0.00120News CoveragePositive NewsOGIOrganigram Global0.9872 of 5 stars$1.39-2.8%N/A-8.3%$191.53M$117.47M0.00860News Coverage Related Companies and Tools Related Companies ORIC Alternatives CTMX Alternatives DRUG Alternatives SOPH Alternatives FDMT Alternatives YMAB Alternatives ENGN Alternatives EPRX Alternatives GNFT Alternatives OGI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRA) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRA Stock Alerts